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Summary
The recent achievement of synthesising a functioning bacterial chromosome marks a
coming of age for engineering living organisms. In the future this should allow the con-
struction of novel organisms to help solve the problems facing the human race, including
health care, food, energy and environmental protection. In this minireview, the current
state of the field is described and the role of synthetic biology in biotechnology in the
short and medium term is discussed. It is particularly aimed at the needs of food technolo-
gists, nutritionists and other biotechnologists, who might not be aware of the potential sig-
nificance of synthetic biology to the research and development in their fields. The potential
of synthetic biology to produce interesting new polyketide compounds is discussed in detail.
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Traditional and Molecular Biotechnology
Traditional biotechnology uses microorganisms for a
variety of purposes. For thousands of years, fermenta-
tion has been used in the food and drinks industry. In
the twentieth century many other microorganism process-
es became important, including the production of anti-
biotics, industrial enzymes and vitamins. With the advent
of genetic engineering, there has been an explosion in
biotechnology in which, not only microorganisms, but
also animals and plants have been used.
Biotechnology is often divided into red, green, white
and blue subdivisions (1). The products and technolo-
gies of red biotechnology are useful in medicine for the
production of drugs, particularly therapeutic proteins.
Red biotechnology also includes the manufacturing pro-
cesses that have evolved out of pharmacogenomics, which
can directly be attributed as benefits coming from se-
quencing the human genome, i.e. personalised medi-
cines, gene therapies and molecular-based diagnostics
(2). The products and technologies of green biotechnol-
ogy are useful to agriculture and animal husbandry. For
example, breeding of agricultural plants and domestic ani-
mals to increase their yields and their nutritive content,
as well as for the improvement of texture, flavour and
complexion of raw materials for the food industry. The
products and technologies of white biotechnology are use-
ful to the chemical and related industries for the pro-
duction of fine and bulk chemicals, plastics, fabric, and
what is emerging as an especially important biotechno-
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logy – production of biofuels as alternative energy sources
to dwindling fossil fuel reserves. Products and technolo-
gies of blue biotechnology are applicable in environmen-
tal protection, particularly for the bioremediation of spe-
cific pollutants such as oil after environmental disasters.
Much of biotechnology utilises microorganisms. Many
microorganisms that are used have been refined to im-
prove the most desirable traits. For example, when peni-
cillin was discovered some 80 years ago (3), its indus-
trial production started with the Penicillium chrysogenum
wild-type isolate that could naturally produce a little
over 2 mg/mL. Today’s industrial strains can produce
more than 100 mg/mL of penicillin, some 50 000 times
more than the wild-type. To achieve this, scientists used
traditional genetic methods of strain improvement, which
were heavily dependent on repeated cycles of muta-
genesis and screening. More modern molecular genetic
techniques encompassing recombinant DNA technolo-
gies were easily incorporated into this process. A typical
industrial strain improvement pipeline would start with
the screening of mutants for higher product yield fol-
lowing random mutagenesis. The mutations in these
high producing mutants would then be mapped using
techniques such as conjugation, transformation, trans-
duction (for the historical overview see references in: 4)
or protoplast fusion (5,6). Usually, the molecular basis
for high production would cover many genetic loci and
would never be discovered. An alternative approach
using recombinant DNA technology is to clone the de-
sirable gene or gene cluster, followed by DNA sequenc-
ing and bioinformatics analysis of the sequence in order
to recognise structural and regulatory regions. Increased
product yield could therefore be achieved either by spe-
cific mutation of these sequences or replacement by more
efficient sequences such as promoters.
Functional genomics has developed as a new broad
field of science for analysing the interactions of biolo-
gical information objects. It includes a number of 'omes':
the most important being genome, transcriptome, pro-
teome, cellome, tissueome and organome (Fig. 1) (7). The
main focus is to discover the properties of the system
being studied rather than concentrating on single parts.
It is aimed to characterize all of the information objects
of the system (such as genes, proteins and ligands) and
find the interactions between the objects. This will often
include engineering networks and objects to understand
and manipulate the regulatory mechanisms and it is
usually necessary to integrate various omes and omics.
Modern research in food science and nutrition is also
moving from classical methodologies to advanced func-
tional genomics in which synthetic biology is the most
recent development. In this context, nutrigenomics (8)
and foodomics (9) have recently been defined as new dis-
ciplines that study food and nutrition domains through
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Fig. 1. Omics pathway. The traditional 'omes' are shown in the top part of the figure. The genome, transcriptome and proteome are
in principle catalogues of the DNA, RNA and protein molecules present in an organism. The cellome, tissuome and organome
combine catalogues of molecules with information about regulatory interactions. The black arrows indicate information flow be-
tween the 'omes' and the resulting hierarchy. The blue arrows indicate modification pathways and the yellow arrows interaction
pathways. The 'omes' in the lower part of the figure are included for completeness, but are less relevant for the topic of this review
(reprinted from ref. 7 with the permission of the Web page owner)
the application of advanced omics technologies. Appli-
cations of nutrigenomics and foodomics include the ge-
nomic, transcriptomic, proteomic, and/or metabolomic
study of foods. This includes compound profiling to es-
tablish authenticity, and/or biomarker detection related
to food quality or safety. There are also omics-based stu-
dies of food bioactivity and the effects of food on human
health. These are all relevant to establishing the safety of
new transgenic foods as well as novel food processing
technologies.
Synthetic Biology
Genetic engineering has been very successful for both
commercial purposes and for fundamental biological
studies. This has usually involved the manipulation of a
small number of genes in an organism. The dream of
synthetic biology was to make designer organisms in
which the whole genome sequence is determined by the
experimenter. Recently Craig Venter’s group has success-
fully synthesized a complete bacterial chromosome and
transplanted it into a cell to obtain a viable living organ-
ism (for details see reference: 10). In this minireview,
we will discuss the importance of synthetic biology for
applications in food technology and biotechnology and
try to pinpoint areas in which progress is possible in the
near future. At present synthetic biology is a rapidly
growing field with numerous potential applications. Our
intention is not to achieve exhaustive coverage of the
entire field, but, rather, to select examples that will alert
scientists from fields such as food technology and nu-
trition to developments, which will become essential for
them in the near future.
Routine oligonucleotide synthesis using phosphora-
midite chemistry has been possible for many years and
can, in principle, produce oligonucleotides of over 200 b
in length. However, in practice, it is most efficient to pro-
duce oligonucleotides of about 50 b. The main innova-
tions that reduced the costs of synthesis were the devel-
opment of techniques allowing the synthesis of many
oligonucleotides in parallel, thus reducing the cost per
oligonucleotide. For synthetic biology applications, the
yield of each oligonucleotide is not a problem. The first
application of oligonucleotides to produce DNA mole-
cules, which were replicated, was to construct linkers to
insert new restriction sites into molecules. A good ex-
ample is the construction of multiple cloning sites for
pUC and related vectors (11). Here the DNA sequences
at the 5’-end of the lacZa gene fragment were altered to
introduce many restriction sites, while still preserving a
viable protein-coding gene. Somewhat later synthetic
genes were constructed by hybridizing and ligating a
series of oligonucleotides. Some care is needed in design-
ing the individual oligonucleotides to avoid problems
with secondary structure and mispairing. However, this
technology has become routine and companies offer gene
synthesis as a routine service. This works well for se-
quences of around 1–5 kb. However, considerably larger
sequences cannot be effectively synthesized in this way,
because significant error frequencies occur.
In 1995 scientists, led by Craig Venter, sequenced the
chromosome of Mycoplasma genitalium, a bacterium with
the smallest known genome of any living organism, only
583 kb in size and encoding 517 genes (12). Comparison
with the genome sequence of another human pathogen,
Haemophilus influenza (13), that encodes around 1700
genes revealed about 250 genes common to both bacteria
that by inference must be absolutely essential for life.
They called these 250 genes the 'minimal genome'. The
essential requirement of each gene was confirmed by di-
rected mutagenesis. An effective experimental approach
to show whether the 'minimal genome' is sufficient to
support life requires the synthesis of bacterial chromo-
somes and their installation in a cell. It was first neces-
sary to show that it was technically possible to achieve
synthesis and activation of a genome known to be func-
tional. In this case, the entire M. genitalium chromosome,
so the discipline of synthetic biology was born. Craig Ven-
ter’s team started construction of the entire M. genita-
lium chromosome from hundreds of pieces of DNA be-
tween 5 and 6 kb in size (10,14), which could be obtained
from routine well-understood assembly of oligonucleo-
tides. The construction of the entire chromosome was
achieved in two steps. In the first step, fragments of
DNA, with sticky 5' and 3' ends were ligated into larger
pieces of DNA using an E. coli host. In the second step,
these large pieces were transformed into the yeast Sac-
charomyces cerevisiae and assembled into a single chromo-
some by the homologous recombination system found in
S. cerevisiae, which is unusual in allowing recombination
of short identical sequences of 50 b or larger (see refe-
rences in: 15) (Fig. 2; 14,16). These experiments showed
that it was technically feasible to synthesize a complete
bacterial chromosome and assemble it in yeast. How-
ever, there was still another major hurdle to overcome:
that of introducing the newly synthesized chromosome
into a bacterial cell in a way that it would function. Al-
though the M. genitalium chromosome had the advan-
tage of small size, the organism is very slow growing, so
that any transplantation experiments would need weeks
of waiting before it was known whether they were suc-
cessful. Therefore, M. mycoides, a close relative of M. ge-
nitalium, which grows much faster, was used. The chro-
mosome of M. mycoides is considerably larger (approx. 1
Mb, 17) than that of M. genitalium (583 kb). After cloning
the chromosome of M. mycoides into yeast and introduc-
ing some genetic changes, it proved possible to trans-
plant it to M. capricolum and produce a viable M. my-
coides strain (18).
Venter’s team then turned to synthesize the chromo-
some of M. mycoides. The researchers started building
their new synthetic chromosome by going DNA shopp-
ing. They bought from a commercial source more than
1000 of 1-kb sequences that covered the whole M. myco-
ides chromosome. To facilitate their assembly in the cor-
rect order, the ends of each sequence had 80 bp that over-
lapped with its neighbours. In order to make sure that
the assembled chromosome would be recognizable as
synthetic, six of the ordered DNA sequences contained
strings of bases that spelt out the names of some of the
people involved in the project (19). However, when they
introduced that synthetic chromosome into M. capricolum
cells nothing happened. The researchers had to correct
mistakes in the chemically synthesized DNA one by one
in the same way informaticians debug newly developed
software. This process took many months of unsuccess-
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fully transplanting these various new chromosomes un-
til the correct combinations were found (16). Proofread-
ing and correcting errors introduced during total synthesis
of large pieces of DNA in a timely manner will be one of
the major challenges for synthetic biology in the future.
The success of Venter's team was achieved at great
expense, an estimated 40 million dollars, and an effort of
20 people working for more than a decade. Despite this
success, creating heavily customized genomes, such as
ones that make fuels or pharmaceuticals, and getting them
to boot up the same way in a cell is not yet a reality.
Professor Paul Keim, a molecular geneticist at Northern
Arizona University said that 'There are great challenges
ahead before genetic engineers can mix, match, and fully
design an organism’s genome from scratch'. However,
before they succeed governmental regulative organisa-
tions, such as Food and Drug Administration in the US,
will need to establish proper regulations for such cases.
Professor Eckard Wimmer from Stony Brook, University
in New York, who led a team that in 2002 created the
first synthetic virus (see references in: 20) believes that
'The possibility of misuse unfortunately exists' (21). In
the meantime Craig Venter has founded a new company,
Synthetic Genomics Inc. (22) which applied for several
patents covering the work. A technology consulting agen-
cy, ETC Group in Ottawa, has argued that these actions
could result in a monopoly on synthesized life (23) but
others are not worried. Given the current climate for grant-
ing and upholding patents of this type, it is unlikely that
the company Synthetic Genomics Inc. will ever become
the Microsoft of synthetic biology. However, one thing is
sure, interesting creatures will be bubbling out of the Craig
Venter Institute laboratories. Because of its importance,
it is not surprising that the synthetic biology immedi-
ately got its scientific, the SynBio (24), and industrial, the
Syndustry (25) (Fig. 3), acronyms. By the synthetic biolo-
gy living beings can be changed on the molecular level,
on the level of the biosynthetic pathway, on the cellular
level and on the level of the entire multicellular organ-
ism (26).
The chemical synthesis of a bacterial chromosome is
an impressive achievement, but the de novo design of bac-
teria is still a distant prospect, because the fundamental
knowledge needed is still lacking. Work by George M.
Church and his group from Harvard Medical School in
Boston and others has tried to adopt an 'engineering’ ap-
proach, i.e. to standardise approaches and develop use-
ful components (27). The International Genetically Engi-
neered Machine (iGEM) Foundation (28) is an organisation
dedicated to the advancement of Synthetic Biology with
open exchange of information. The main concept is to
develop standard parts to allow the construction of or-
ganisms, which can perform a particular task. Each year
it sponsors a competition for student teams to achieve
this aim (there were 190 teams for the iGEM 2012 com-
petition). There is a catalogue of standard parts (28) and
the aim is to make Synthetic Biology an engineering dis-
cipline: most of a construction should use robust stan-
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Fig. 2. Illustration of some important steps in the construction of a synthetic bacterial chromosome. The two-step chromosome
construction shows in cartoon form how the whole Mycoplasma genitalium chromosome was assembled in yeast from shorter DNA
fragments assembled in E. coli. The same strategy was used to assemble the M. mycoides chromosome and the assembly steps are
shown in more detail. After successful introduction of the synthetic M. mycoides chromosome into a bacterial cell, the proteome was
compared to that of wild-type M. mycoides using 2-D gel electrophoresis to confirm that a normal protein complement was present.
The synthetic chromosome contained a b-galactosidase gene allowing colonies containing the synthetic chromosome to be recognised
by their blue colour on media containing X-gal (modified from refs. 14 and 16 with the permission of publishers)
dard parts with well understood properties. The BioBricks
Foundation (29) supports similar aims and has estab-
lished standards for parts ('BioBricks'). Many of the parts
are designed for microorganisms, but there are also parts
for animals and plants. One proof of principle was to
use a BioBrick approach to introduce genes for the sweet
protein brazzein and the flavour-inverter protein mira-
culin, which makes sour foods taste sweet, into the plant
Arabidopsis thaliana (30). This sort of development will
move the emphasis of genetic engineering from today’s
situation in which genetic engineering experts drive the
field to one where the engineer sits down and designs
the desired modification using a standard toolkit. Food
technologists will be able to decide favourable compo-
nents for food and design plants and animals with the
correct properties, without knowing all the subtle details
of vector design and cloning strategies.
In many cases, it will probably be more effective to
redesign existing organisms rather than building a new
organism de novo. For many years, it has been possible
to use directed mutagenesis to change one gene in an
organism. Recently methods have been developed for
introducing many mutations simultaneously (31). These
depend on the properties of the recombination protein b
of bacteriophage l, which allows recombination between
short regions of homology. If an oligonucleotide is intro-
duced into an E. coli cell whilst it is replicating, protein b
can promote recombination of the oligonucleotide with
the chromosome at the replication fork. The authors de-
signed an automatic system for carrying out repeated
cycles of transformation with a mixture of oligonucleo-
tides so as to achieve a high frequency of recombinants
in multiple genes without selection; this approach was
called multiplex automated genome engineering (MAGE).
The system was tested by targeting 24 genes simultane-
ously to try to improve the production of the industrially
important isoprenoid lycopene. Four of the genes were
targeted for inactivation by introducing stop codons,
whereas the other 20 genes were targeted for higher ex-
pression, trying to improve translational efficiency by
modifying the ribosome binding sites (RBS). As the opti-
mal ribosome binding sites were not known, a mixture
of oligonucleotides was synthesized for each RBS using
a choice of nucleotide at several sites. This approach re-
sulted in a five-fold increase in lycopene production
within three days of MAGE cycling. A more ambitious
aim is to reprogram the genetic code of an organism.
This recoding could prevent expression of foreign genet-
ic material giving protection against viruses and pro-
viding genetic containment for recombinant genes. If it
were possible by recoding to introduce novel amino acids
in protein synthesis, there would be many potential com-
mercial applications. A first step to this aim has been
taken by eliminating the use of the amber stop codon
(UAG) in E. coli, thus providing a free codon for repro-
gramming (32). There are 314 E. coli genes, which use a
UAG stop codon and a strain was produced with all 314
replaced by UAA stop codons. The approach used MAGE
to construct strains with 10 changes in the same region
of the chromosome. The mutations in these strains were
then assembled into a single strain using conjugative
assembly genome engineering (CAGE). This impressive
feat shows that large scale reengineering of existing strains
is possible. However, the methods used to achieve a high
efficiency of MAGE also resulted in other random muta-
tions occurring in the genome, which could be a consid-
erable drawback for engineering strains. However, it may
be possible to improve the methodology to reduce this
problem.
It is claimed that the use of synthetic biology, or
Syndustry, will allow the construction of superior indus-
trial microorganisms suitable for the production of novel
drugs, raw materials for the food industry, chemicals
and plastics (Fig. 3). There is also considerable interest
in the production of alternative fuels, as well as for the
bioremediation of pollution. However, most of the con-
crete examples of synthetic biology do not involve sys-
tems of industrial interest. Synthetic biology does not
employ novel methodologies, but rather extends the
scope of existing methods of genetic manipulation. These
facts raise the question as to whether synthetic biology
is a passing fad or is an important field, which biotech-
nologists should take seriously. We believe the latter, be-
cause synthetic biology introduces a fundamental differ-
ence in how biotechnologists should operate. Classical
biotechnology selects a microorganism and the design of
the process is constrained by the physiological proper-
ties of the organism. Thus, in a secondary metabolite fer-
mentation using a Streptomyces strain, fermentation will
occur over many days usually using a complex fed batch
process with problems arising from the rheological prop-
erties of the fermentor contents. Although strain im-
provement programmes improve yield, they do not alter
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Fig. 3. The cartoon illustrating possible applications of synthetic
biology (reprinted from ref. 25 with the permission of the Web
page owner)
the fact that the process engineering in dominated by
the physiological properties of the organisms used. Syn-
thetic biology makes the very ambitious claim that the
biotechnologist can design the organism using standard
procedures in a similar way to the engineering design of
other components of the process. At present, the know-
ledge base only allows limited design possibilities. How-
ever, the demonstration that it is possible to synthesize
bacterial chromosomes and the continuing development
of standard parts for genetic manipulation will lead to
rapid improvements. Synthetic biology is already being
integrated into pipelines for the incremental improve-
ment of existing processes, but will really come of age in
industry, when novel processes are introduced, which
were not feasible with more traditional methods. In a
few years, every biotechnologist will have to understand
the fundamentals of synthetic biology.
Synthetic Biology for Large Gene Clusters for
the Biosynthesis of Natural Products
Progress in synthetic biology will be predicated on
the development of better and cheaper technology to syn-
thesize long DNA sequences. This will be stimulated by
the demand for DNA synthesis from different projects. It
seems unlikely that, in the near future, many groups will
be synthesizing complete bacterial chromosomes. An in-
teresting target for synthetic biology is natural product
biosynthetic clusters. These are frequently large (50–150
kb in size), so they need comparable technology to that
for bacterial chromosomes. However, they are much bet-
ter understood, so there will be an immediate pay-off in
terms of functioning clusters. Our laboratories have been
working on pharmaceutically important natural products
that are synthesized by Type I and Type II polyketide
synthases (PKS) (e.g. 33–35). There has been much work
on the in vivo combinatorial biosynthesis of polyketides
for the past two decades, but the field remains in its in-
fancy (see references in: 36), mainly because of the prob-
lem that most constructs have very low product yields.
In our laboratories we have developed an expert system
for the in silico drug design and discovery, 3DIS (37).
The expert system consists of two generic program pack-
ages, ClustScan (38,39) and CompGen (40,41), and two
custom databases CSDB and r-CSDB (see databases at:
42). These two suites of programs allow rapid mining of
large genomic and metagenomic data sets for modular
polyketide synthases (PKS), non-ribosomal peptide syn-
thetases (NRPS) and hybrid polyketide synthase/non-
-ribosomal peptide synthetase (PKS/NRPS) biosynthetic
gene clusters, collectively called Thiotemplate Modular
Systems (TMS) (43). The annotation is performed with
hierarchical structuring from DNA sequence into poly-
peptides and then catalytic enzyme domains, as well as
storage and graphical presentations of the data. A pre-
diction of the most likely chemical structures produced
by these enzyme-catalysed reactions is also given, there-
by providing comprehensive annotation 'from genes to
compounds’ (39,44,45). As mentioned above, these anno-
tations and likely chemical structures have been used to
build two custom databases, one of which is a reposi-
tory of known compounds, CSDB, and the other a repo-
sitory of novel recombinant products, r-CSDB, that can
be used for in silico screening with computer aided drug
design technology (46). The program packages use pro-
files derived from hidden Markov models (HMMs) (47)
to locate catalytic domains in proteins and then, through
consideration of the collected set of domain structures,
predict the likely enzyme products. It is possible to use
standard profiles (Pfam) (48), proprietary profiles sup-
plied with the program and also for the user to supply
their own proprietary profiles (e.g. built with profile
HMMs for protein sequence analysis). Chemical struc-
tures of metabolites are stored and output as extended
isomeric SMILES (Simplified Molecular Input Line Entry
System, 49) strings. One of the important advantages of
ClustScan and CompGen is that they make it easy to iden-
tify potential sequencing and assembly errors and inter-
esting features of gene clusters (38,41).
The r-CSDB database contains predicted entirely
novel recombinant products. The recombination sites are
chosen on the basis of modelling homologous recombi-
nation between clusters, because it seems likely that this
will alleviate the problems associated with junctions en-
countered during attempts at combinatorial biosynthe-
sis. At present there are 47 parental PKS gene clusters,
777 cluster pairs and 20187 recombinant gene clusters in
r-CSDB database (Fig. 4) that generates 11 796 unique
compounds. Like CSDB, r-CSDB also contains all data
starting with gene cluster recombinant DNA sequence,
the DNA and protein sequences of genes, modules and
domains and of the recombinant gene clusters present in
FASTA formats. It also contains all known polyketide and
peptide building blocks in the form of isomeric SMILES
(49), along with the programmed logic that allows total
prediction of linear and partial prediction cyclic polyke-
tide and peptide chains and aglycons in the 2-D or 3-D
forms suitable for further computer processing. Parental
and recombinant linear chain and agycons can be also
visualised using Jmol (50) or ChemAxon (51). The r-CSDB
database is also fully searchable using CompGen suit of
programs of TMS gene cluster annotations as well as re-
combinant compound structures. As CSDB, the r-CSDB
data can also be manipulated using a number of con-
ventional bioinformatic tools.
In r-CSDB we have DNA sequences of all recombi-
nant gene clusters generated so far. They could now be
synthetized, cloned in an appropriate vector and ex-
pressed in a suitable host. If the DNA sequences of sever-
al parent clusters were synthesized in suitable segments,
a large number of different recombinants could be con-
structed from the same material. In general, the number
of possible recombinants scales with the square of the
number of parent clusters available. A synthetic biology
approach needs suitable vectors. One such vector, pKW-
201, is described by Starcevic et al. (40) and would be
useful for its ability to transfer gene clusters between dif-
ferent plasmid vectors and/or chromosomes of different
species using the rpsL-based constructs (52). A major issue
for the pharmaceutical industry is maintaining a conti-
nuous supply of promising new leads for drug develop-
ment. We propose that recombinatorial biosynthesis and
synthetic biology offers a new and exciting strategy where-
by large and chemically diverse libraries of polyketides
and non-ribosomal peptides can first be screened in silico
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and then generated in the laboratory for further new lead
development.
When a commercially interesting cluster has been
identified, synthetic biology can be employed to gener-
ate an industrial microorganism. The ideal organism
would probably be a fast-growing unicellular microor-
ganism rather than a mycelial slow-growing Streptomyces
strain. As synthetic biology matures, it will become pos-
sible to manipulate a suitable organism to provide the
necessary precursors and switch on the biosynthesis genes
at the correct time. At present it should be possible to
express the cluster in a suitable Streptomyces host using
known regulation systems to induce the genes at the
correct time. For instance, it would be possible to use
Streptomyces rimosus, which has disperse growth and a
proven track record for production of high titres of a
polyketide (53). Given that many polyketides and non-
-ribosomal peptides are used clinically (54), this new ex-
pert system (37) and synthetic biology come at an im-
portant time for hit and lead identification.
Conclusions and Future Prospects
Apart from the construction of industrial microorgan-
isms reviewed by Chen et al. (55) and by Krivoruchko
et al. (56) in which structural synthetic biotechnology as
a new field in biotechnology was proposed for the im-
proved production of industrial enzymes (57), natural
product metabolites (58), other pharmaceutical products
(59) and for biofuel production (60), there are numerous
other applications of synthetic biology. For example, it
was proposed that the synthetic biology can be applied
in evolutionary and toxicology studies (61,62) and that it
will even move into clinical studies (63,64) for the treat-
ment of infectious diseases and cancer; as well as for the
vaccine development, microbiome engineering, cell the-
rapy, and regenerative medicine. The chemical synthesis
of single genes up to about 5 kb in length is now routine
and not very expensive. The synthesis of longer DNA
sequences (e.g. longer than 100 kb) is still very difficult
and expensive; a very important constraint is the pre-
sence of mutations, which are time-consuming to elimi-
nate. The speed and costs of such DNA synthesis will
only drop significantly if there is commercial demand,
analogous to the drop in DNA sequencing costs fuelled
by the Human Genome Project. It seems unlikely that
there will be enough demand for the synthesis of com-
plete bacterial chromosomes in advance of technology
improvement, because the short term commercial ad-
vantages are unclear. A more realistic target is clusters
for the biosynthesis of natural products, which range in
size from about 10–200 kb. The products of these clus-
ters are of proven commercial values and, as pointed out
in this review, fragments of the clusters can be used for
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Fig. 4. Screenshots from r-CSDB: a) r-CSDB homepage (left) and all recombinant products in the database (right), b) the data of 5th
recombinant between hybrid PKS/NRPS Rap and PKS Tca gene clusters and c) the graphical presentation of homeologous recom-
bination (see database at: 42)
various combinatorial processes, reducing the synthesis
costs of each novel cluster. Rapid and cheap synthesis of
longer DNA sequences would open up possibilities for
novel applications in higher risk fields and make the rou-
tine synthesis of whole bacterial chromosomes attractive.
It also seems likely that the movement to establish
an engineering approach to synthetic biology (28,29) will
lead to a rapid increase in applications once the library
of standard parts reaches a critical size. This will mean
that most of the components needed for any application
already exist in a standard tested form and most of the
work is selecting appropriate components and building
them together. This approach generates an increasing
need for computational tools that can support synthetic
biology. A range of algorithms has been developed that
can be used for different applications. The key existing
tools and suggestions how informatics can help to shape
the future of synthetic microbiology is reviewed in a num-
ber of articles (65–68). It seems that the synthetic biology
software will soon drive the wet lab implementation of
DNA sequences.
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